In this Open Briefing®, Andrew discusses: • Four new OEM proposals under consideration • Growing market enquiries and successful trade shows including ISBER and SLAS • Six months trading results, period ended 31 December 2018 • Changing revenue mix to ongoing consumables sales • Increasing production and delivery under US$11.9m Labcon contract Open Briefing interview…
Discover More >The “Pulmonary Biobank Consortium, CIBER of Respiratory Diseases (CIBERES) – ISCIII (Madrid), Institut d’Investigació Sanitària de les Illes Balears (IdISBA) – Hospital Universitari Son Espases, Mallorca, Spanish Biobank Network” recently presented a scientific poster about Bluechiip technology in the International Society of Biobanks and Environmental Repositories (ISBER) Symposium this February 2019 in Berlin. See CIBERES…
Discover More >In this Open Briefing, Andrew discusses: Labcon’s official release and marketing of Bluechiip enabled product Accelerating sales and production scaling progress Reader production status and approvals Partner progress and cash position Download the full document here: https://www.asx.com.au/asxpdf/20190130/pdf/4425m31s7m9cnn.pdf
Discover More >Download the presentation shown during the past AGM on the 26th of November 2018 https://www.asx.com.au/asxpdf/20181126/pdf/440mb0vpc9v670.pdf
Discover More >In this Open Briefing, Andrew discusses: Recent #7.5M capital raise and the updated $15.9M over 3 yr Labcon agreement Recent customer activity and finalisation and product portfolio Recent 4C and cashflow forecast Partner and opportunity pipeline Read the full announcement here: https://www.asx.com.au/asxpdf/20181018/pdf/43zcy4f8442yrg.pdf
Discover More >Read the full announcement here: https://www.asx.com.au/asxpdf/20181018/pdf/43zcy1zcj8cw0r.pdf
Discover More >Read the full announcement here: https://www.asx.com.au/asxpdf/20181003/pdf/43yxlyhfbpypz0.pdf
Discover More >Download the full announcement here: https://www.asx.com.au/asxpdf/20180910/pdf/43y5vwqsg73qxh.pdf BLUECHIIP RAISES $5.5 MILLION AND ANNOUNCES SHARE PURCHASE PLAN Bluechiip Limited (Bluechiip or the Company, ASX: BCT), a leader in the development of sample-tracking technology for harsh environments, today announced it has successfully raised $5.5 million via an oversubscribed placement to sophisticated and professional investors. The placement comprised…
Discover More >Download the ASX announcement here: https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02017004 In this Open Briefing®, Andrew discusses: · A$15.9m, three-year deal with Labcon North America · Expectation for margins and NPAT and operating cash flow positive from this one contract · Ramp up of production and consideration of working capital sources · Adjacent markets beyond this Labcon order that can…
Discover More >Bluechiip signs three-year $A15M supply deal with Labcon Highlights: New three-year deal added to existing Labcon North America Development and Supply Agreement $US4.2m ($A5.8m) two-year purchase order for Chips, readers, software and engineering services $US7.4m ($A10.1m) agreed minimum for third year See full announcement here: https://www.asx.com.au/asxpdf/20180829/pdf/43xt21br9gcvjd.pdf Bluechiip Limited [ASX: BCT] a leader in the development of…
Discover More >